Western blot:A suitable range of concentrations of this antibody for WB detection is 2-10 µg/ml.
WB analysis mouse hippocampal tissue lysate expressing BCL-2.
Cat# RPA10415 was used as primary antibody.
IHC: A suitable range of concentrations of this antibody for IHC is 2-10 µg/ml.
Immunohistochemical analysis of PPFE rabbit hippocampal tissue expressing BCL-2.
Cat# RPA10415 was used as primary antibody, dilution 1:200.
Immunohistochemical analysis of PPFE human endometrial tissue expressing BCL-2.
Cat# RPA10415 was used as primary antibody, dilution 1:500.
Source:
Polyclonal BCL-2antibody was produced from sera of mice immunized with synthetic protein containing BCL-2 antigenic determinants.
Species reactivity:
Human,Mouse,Rat,Rabbit
Purification:
Serum IgG fraction was purified by Protein G affinity chromatography.
Presentation:
Lyophilized from sterile filtered PBS solution at a concentration of 1mg/ml.
Reconstitution:
A quick spin of the vial followed by reconstitution in distilled water. This solution can then be diluted into other buffers
Storage:
The lyophilized antibody is stable for at least 1 year from date of receipt at -20° C.
Upon reconstitution, this antibody can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months without detectable loss of activity.
Avoid repeated freeze/thaw cycles.
Usage:
This antibody product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
BCL2
Related Publications:
akt activation emulates chk1 inhibition and BCL2 overexpression and abrogates g2 cell cycle checkpoint by inhibiting brca1 foci
J. Biol. Chem.,
May 2010;
10.1074/jbc.M110.104372.
ifn restores breast cancer sensitivity to fulvestrant by regulating stat1, ifn regulatory factor 1, nf-b, BCL2 family members, and signaling to caspase-dependent apoptosis
Mol. Cancer Ther.,
May 2010;
9:
1274 - 1285.
analysis of pro-apoptotic BCL2 family member initiators bim, bid, and bbc3 in retinal ganglion cell death
Invest. Ophthalmol. Vis. Sci.,
Apr 2010;
51:
2118.
BCL2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer
Clin. Cancer Res.,
Apr 2010;
16:
2138 - 2146.
BCL2 is not required for the development and maintenance of leukaemia stem cells in mice
Carcinogenesis,
Mar 2010;
10.1093/carcin/bgq062.
